development of a multivalent vaccine against respiratory syncytial virus

24
Development of a multivalent vaccine against Respiratory Syncytial Virus By Lucious Vaughn Alabama State University Department of Biological Sciences

Upload: shani

Post on 23-Feb-2016

36 views

Category:

Documents


0 download

DESCRIPTION

Development of a multivalent vaccine against Respiratory Syncytial Virus. By Lucious Vaughn Alabama State University Department of Biological Sciences. Introduction. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

Development of a multivalent vaccine against Respiratory Syncytial Virus

By Lucious Vaughn

Alabama State UniversityDepartment of Biological Sciences

Page 2: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

Introduction

Human Respiratory Syncytial Virus (RSV) is the most common cause of bronchiolitis and pneumonia among infants and children, with almost everyone having contracted RSV at least once by the age of 2.

Page 3: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

12.50%9.70%

8.90%

8.90%11.40%

4.30%

44.30%

Viruses That Cause Respiratory Illness

Influenza A or B, 12.5%

Parainfluenza, 9.7%

RSV, 8.90%

Metapneumovirus, 8.9%

Other, 11.4%

Adenovirus, 4.3%

Entero/Rhinovirus, 44.3%

Page 4: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

The science of RSV

• Family: Paramyxoviridae Genus: Pneumovirus

• Negative sense single strand RNA virus translated into 11 proteins

Page 5: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

The Goal

To design a multivalent vaccine against Respiratory Syncytial Virus

• Multivalent- having several sites of attachment for an antibody or antigen. In this case F, M2, & G proteins.

Page 6: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

The Virus

Page 7: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

Genomics of RSV

Page 8: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

The F (fusion) protein

• Viral penetration • Syncytium formation• High titers of neutralizing antibodies

Syncytia

Page 9: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

The G (attachment) protein

• Aides in the attachment of the virus to the host.

• Has epitopes recognized by the host antibody response.

Page 10: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

The M2 (matrix) protein

• M2-1:Transcription elongation factor

• M2-2:Regulates viral transcription

• Induces CD8 T-cells

Page 11: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

The F gene Entire length of F gene = omitted on purpose

Page 12: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

The M2 geneEntire length of M2 gene = omitted on purpose

Page 13: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

The G geneEntire length of G gene = omitted on purpose

Page 14: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

Newly designed multivalent gene FM2GSal I- R.E. digestion end Nco I- R.E. digestion end

Page 15: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

pET-32a(+) Vector

Page 16: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

Linear view of pET-32a(+) Vector showing Restriction Enzyme sites

Sal I Nco I

Page 17: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

Insertion and Cloning of multivalent gene with vector

Page 18: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

Test ligation

550 bp

Restriction enzyme analysis of multivalent gene on agarose gel

Lane-1: 1kb ladderLane-2: RFM2G cut with Nco ILane-3: pET-32 cut with Nco I and Sal ILane-4: RFM2G cut with Nco I and Sal ILane-5: 100kb ladder

1 2 3 4 5

Page 19: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

The Methods

CLONING

PROTEIN EXPRESSION

PROTEIN PURIFICATION

IMMUNIZATION

Page 20: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

Expression of protein

E. coli BL21 cells pET-32 with FM2G

E. c

oli

Protein expression

Page 21: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

SDS-PAGE analysis of multivalent protein

Lane-1: SDS-MarkerLane-2: Cytoplasmic ExtractLane-3: Soluble FractionLane-4: PelletLane-5: Purified FM2G protein

38KDa

1 2 3 4 5

Page 22: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

Western blot analysis of the multivalent protein

Lane-1: PelletLane-2: Soluble FractionLane-3: Cytoplasmic Extract Lane-4: Magic Marker

1 2 3 4

38KDa

Page 23: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

Conclusion• Multivalent gene cloned into pET-32a vector

• Successful transformation

• Successful protein expression

• Confirmation analyses identified the created protein

• Immunization testing in various specimens is presently ongoing

Page 24: Development of a multivalent vaccine against  Respiratory  Syncytial  Virus

REFERENCES

• 1. Collins, P.L., et al., Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. PNAS, 1986. 83: p. 4594-4598.

• 2. Domachowske, J.B. and H.F. Rosenberg, Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin. Micro. Rev., 1999. 12(2): p. 298-309.

• 3. Hacking, D. and J. Hull., Respiratory syncytial virus- Viral biology and the host response. Journal of infection., 2002. 45: p. 18-24.